Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
Beta Finch - Regeneron - REGN - EN cover art

Beta Finch - Regeneron - REGN - EN

Beta Finch - Regeneron - REGN - EN

Written by: Beta Finch
Listen for free

About this listen
AI-powered earnings call analysis for Regeneron (REGN). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.2026 Beta Finch Economics Personal Finance
Episodes
  • Regeneron Q3 2026 Earnings Analysis
    Oct 30 2026
    More earnings analysis: https://betafinch.com
    Groups: PHARMA (https://betafinch.com/groups/PHARMA)
    ──────────
    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown, where we turn dense earnings calls into conversations you'd actually want to have with a friend. I'm Alex.

    **JORDAN:** And I'm Jordan. Alex, we've got a big one today.

    **ALEX:** We really do — Regeneron, ticker REGN, reporting Q3 2026 results. But before we jump in, our standard disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Important stuff. Okay, so Alex, let's set the scene — the stock popped nearly 13% on this print. That's not a small move for a company this size.

    **ALEX:** No kidding. And when you look at the numbers, it's easy to see why. Total revenue grew 36% year-over-year to $5.1 billion. Non-GAAP earnings per share jumped 70% to $20.07. This is the third straight quarter of double-digit growth on both the top and bottom line.

    **JORDAN:** And it wasn't just one product carrying the load. Dupixent, EYLEA HD, and Libtayo — their three biggest commercial brands — each hit all-time-high quarterly sales. Two quarters in a row, actually.

    **ALEX:** Let's break those down one at a time, because the Dupixent number alone is wild. Global sales hit $6.5 billion, up 35% at constant currency. In the U.S. specifically, sales crossed $5 billion for the first time ever.

    **JORDAN:** For a drug that's approaching its tenth year on the market, that's genuinely remarkable. Most blockbuster drugs plateau or start fading by year ten — Dupixent is accelerating. It's the leading biologic in eight of its nine approved indications.

    **ALEX:** Then there's EYLEA HD, the next-gen eye medicine. U.S. sales hit $699 million, up 62% year-over-year, and it now makes up almost two-thirds of their retinal franchise. Physician demand grew 20% sequentially.

    **JORDAN:** Though I'll note — the older EYLEA formulation is declining fast, down 41%, as biosimilar competition eats into that market. So this is really a story of EYLEA HD cannibalizing its predecessor successfully, which is the right problem to have.

    **ALEX:** Right, it's a managed transition, not just pure growth. And then Libtayo, their cancer immunotherapy — $550 million globally, up 51%. It's now running at an annual pace of about $2.2 billion.

    **JORDAN:** Now here's the part that I think got Wall Street really excited — the Sanofi relationship. Regeneron finished repaying its development cost balance to Sanofi, which means for the first time, they're collecting their FULL share of Dupixent collaboration profits. No more clawbacks eating into the number.

    **ALEX:** And on top of that, they announced an expanded alliance — four next-generation long-acting antibodies targeting the same pathways that made Dupixent a hit. Regeneron gets a $1 billion upfront payment landing in Q4, and going forward, they split both R&D costs and profits 50/50 with Sanofi. That's a much better deal structurally than before.

    **JORDAN:** CEO Leonard Schleifer called it leading "the next era of type 2 inflammation medicines." And CSO George Yancopoulos made an interesting point in the Q&A — he argued their antibodies are "naturally derived" from their humanized mouse platform, versus competitors using heavily engineered older antibodies, which historically have more immune and safety issues.

    **ALEX:** That's classic Regeneron — leaning on their genetics-driven science story. Speaking of which, the CIDEB program in NASH, or fatty liver disease, might be the most eye-popping pipeline data point this quarter.

    **JORDAN:** Yeah, this one's worth pausing on. Regeneron's genetics database found people with a naturally occurring loss-of-function in the CIDEB gene have dramatically lower rates of fatty liver di

    This episode includes AI-generated content.
    Show More Show Less
    7 mins
  • Regeneron Q2 2026 Earnings Analysis
    Jul 31 2026
    More earnings analysis: https://betafinch.com
    Groups: PHARMA (https://betafinch.com/groups/PHARMA)
    ──────────
    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into Regeneron's second quarter 2026 results, and Jordan, this was a big one.

    JORDAN: A really strong quarter across the board. But first, the standard note — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    ALEX: Right. So let's set the scene — before diving into numbers, the call opened with a tribute to longtime board member Art Ryan, who passed away this week. He'd been on Regeneron's board for over two decades, previously ran Prudential. A nice moment of the human side of these calls.

    JORDAN: Definitely worth noting. Now, onto the business — total revenue was up 17% year-over-year to $4.3 billion, and non-GAAP EPS grew 11% to $14.29. That's their second straight quarter of double-digit growth on both lines.

    ALEX: And the headline here is really the trio of record quarters — Dupixent, EYLEA HD, and Libtayo all hit all-time highs for quarterly sales.

    JORDAN: Let's start with Dupixent since it's the big one. Global net sales hit $6 billion, up 38% on a constant currency basis. U.S. sales alone grew 42% to $4.6 billion. That's a drug now serving over 1.5 million patients across nine approved indications.

    ALEX: Nine! That's dermatology, asthma, nasal polyps, COPD, eosinophilic esophagitis — it just keeps expanding. And here's something investors should watch: Regeneron fully repaid its $3.1 billion development balance owed to Sanofi. That balance had been suppressing collaboration revenue — about $930 million lower in 2025 and $530 million in the first half of this year.

    JORDAN: So starting in Q3, Regeneron gets to keep its full share of collaboration profits. That's a real step-up to the bottom line going forward, not tied to any new sales growth — just an accounting unlock.

    ALEX: Exactly. Now let's talk EYLEA HD — this one's on fire. U.S. net sales just under $600 million, up 52% year-over-year. And notably, this was the first quarter EYLEA HD sales actually exceeded the original EYLEA.

    JORDAN: That's the conversion story playing out. EYLEA HD now makes up about 60% of the franchise, up from 34% a year ago. Meanwhile legacy EYLEA sales fell 45% as patients and doctors shift over — plus there's now biosimilar competition entering that older product's market.

    ALEX: They're also awaiting FDA approval on an EYLEA HD prefilled syringe, which could drive even more adoption. Management sounded confident that could land by year-end.

    JORDAN: And rounding out the trio, Libtayo — their oncology drug — hit $489 million globally, up 29%. It's gaining real traction in non-small cell lung cancer, now capturing 20% of new prescriptions, double what it was just last year.

    ALEX: Let's talk pipeline for a second, because Regeneron's whole philosophy here is "don't bet on one horse." They've got roughly 50 active clinical programs.

    JORDAN: A few near-term catalysts stood out to me. There's cemdisiran, their siRNA therapy for myasthenia gravis, with an FDA decision expected in November — that could be the first siRNA approved for that disease. There's also garetosmab for a rare bone disease called FOP, with an FDA decision expected as soon as August.

    ALEX: And on the bigger picture front, they're moving into Phase III trials later this year for both their obesity program — a GLP-GIP combo called olatorepatide — and their anticoagulation program targeting Factor XI, which is a different approach than the traditional blood thinners on the market.

    JORDAN: One thing that came up repeatedly in Q&A was the Sanofi relationship. CEO Leonard Schleifer confirmed they're in "productive early discussions" with Sanofi about expanding the collaboratio

    This episode includes AI-generated content.
    Show More Show Less
    7 mins
  • Regeneron Q1 2026 Earnings Analysis
    Apr 29 2026
    # Beta Finch Podcast Script: Regeneron Q1 2026 Earnings

    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex.

    **JORDAN:** And I'm Jordan. Today we're breaking down Regeneron's first quarter 2026 results, and folks, this biotech giant is firing on all cylinders.

    **ALEX:** Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Absolutely. Now Alex, let's talk numbers because Regeneron just posted some impressive results. Revenue jumped 19% to $3.6 billion, and non-GAAP earnings per share grew 15%. Those are solid double-digit growth numbers across the board.

    **ALEX:** What really caught my attention is the DUPIXENT story. This drug is becoming an absolute juggernaut - global net sales hit $4.9 billion in the quarter, up 31% on a constant currency basis. Jordan, we're looking at annualized sales approaching $20 billion for this single drug.

    **JORDAN:** It's incredible when you put it in perspective. DUPIXENT is now treating over 1.4 million patients worldwide, and they keep expanding into new indications. This quarter alone, they got approval for allergic fungal rhinosinusitis and chronic spontaneous urticaria in younger patients. It's like they're building a franchise within a franchise.

    **ALEX:** Speaking of franchises, let's talk about their eye drug portfolio. EYLEA HD had a strong quarter with U.S. sales of $468 million, up 52% year-over-year. But here's the interesting dynamic - while EYLEA HD is growing rapidly, the original EYLEA is declining as expected, down 36%. It's a classic product transition story.

    **JORDAN:** And there's still some uncertainty hanging over that transition. They're waiting on FDA approval for the EYLEA HD prefilled syringe, which missed its April deadline. Management expects a decision this quarter, but it shows how regulatory timing can impact even established companies like Regeneron.

    **ALEX:** Now, what really excited me during the call was the pipeline discussion. CEO Leonard Schleifer and Chief Scientific Officer George Yancopoulos laid out some compelling near-term catalysts. They've got this complement inhibitor cemdisiran for myasthenia gravis that showed really impressive Phase 3 results.

    **JORDAN:** The data on that was striking. Their drug delivered a 2.3-point improvement compared to placebo, which actually outperformed existing treatments that showed 1.6 to 1.9 points in their trials. Plus, it's dosed quarterly versus every two weeks for competitors. That convenience factor could be huge.

    **ALEX:** And then there's their obesity play with olatorepatide. This is where Regeneron is trying to differentiate in the crowded GLP-1 space. Their strategy is fascinating - they want to combine this obesity drug with their cholesterol drug Praluent.

    **JORDAN:** George Yancopoulos made a compelling pitch on this during the Q&A. He basically said, imagine you have a GLP-1 that works as well as the best ones out there, but also lowers your bad cholesterol by 50% and reduces cardiovascular risk. Why would anyone choose a different GLP-1? It's an interesting value proposition in a competitive market.

    **ALEX:** What struck me about that answer is how confident they sounded. Yancopoulos said it would be a "no-brainer" choice for physicians and patients. That's either brilliant positioning or they're setting themselves up for disappointment. Time will tell.

    **JORDAN:** One moment that really stood out was when they announced they're giving away their new gene therapy, Otarmeni, for free in the U.S. This treats genetic hearing loss in children, and they got FDA approval just last week.

    **ALEX:** That was such an interesting strategic decision. Schleifer said they'r

    This episode includes AI-generated content.
    Show More Show Less
    8 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet